Dipraglurant
ADX48621-301
Phase 3 small_molecule terminated
Quick answer
Dipraglurant for Parkinson Disease is a Phase 3 program (small_molecule) at Addex Therapeutics with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Addex Therapeutics
- Indication
- Parkinson Disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated